-
Norris Medicines Receives Orphan Drug Designation from FDA for NM-002 in Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NM-002 for the treatment of idiopathic pulmonary fibrosis (IPF).
-
Norris Medicines Announces Positive Phase 2a Data for NM-002 in Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced positive topline results from the Phase 2a clinical trial evaluating NM-002 in patients with idiopathic pulmonary fibrosis (IPF).
-
Norris Medicines Raises $60 Million in Series B Financing to Advance Development of NM-002 for Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced the closing of a $60 million Series B financing to support the continued development of NM-002 for the treatment of idiopathic pulmonary fibrosis (IPF).
-
Norris Medicines Announces Positive Phase 2 Data for NMS-001 in Patients with Advanced Solid Tumors
Norris Medicines Ltd. (NASDAQ: NRIS), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, today announced positive Phase 2 data for NMS-001, its lead oncology asset, in patients with advanced solid tumors.
-
Norris Medicines to Present Data from Phase 2 Trial of NMS-001 at the AACR Annual Meeting 2023
Norris Medicines Ltd. (NASDAQ: NRIS), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, today announced that it will present data from the Phase 2 trial of NMS-001, its lead oncology asset, at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Norris Medicines Announces Closing of $100 Million Series C Financing
Norris Medicines Ltd. (NASDAQ: NRIS), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, today announced the closing of a $100 million Series C financing.
-
Norris Medicines Announces Appointment of Dr. David Hong as Chief Medical Officer
Norris Medicines Ltd. (NASDAQ: NRIS), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, today announced the appointment of Dr. David Hong as Chief Medical Officer.
-
Norris Medicines to Present Preclinical Data for NMS-001 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Norris Medicines Ltd. (NASDAQ: NRIS), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, today announced that it will present preclinical data for NMS-001, its lead oncology asset, at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting.
-
Norris Medicines Strengthens Senior Leadership Team with Appointment of Anthony Gray as Chief Business Officer
Norris Medicines Ltd., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of life-threatening viral infections based on its proprietary single-acting strand displacement oligonucleotide (SSO) technology, today announced the appointment of Anthony Gray as Chief Business Officer.
-
Norris Medicines to Present at the 2023 Hamlyn Centre Conference on RNA Therapeutics
Norris Medicines Ltd., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of life-threatening viral infections based on its proprietary single-acting strand displacement oligonucleotide (SSO) technology, today announced that it will present at the Hamlyn Centre Conference on RNA Therapeutics.
-
Norris Medicines Announces Positive Interim Data from Phase 2a Trial Evaluating NM-002 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in Hospitalized Infants
Norris Medicines Ltd., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of life-threatening viral infections based on its proprietary single-acting strand displacement oligonucleotide (SSO) technology, today announced positive interim data from its ongoing Phase 2a trial evaluating NM-002 for the treatment of respiratory syncytial virus (RSV) infection in hospitalized infants.